Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Increasing sales is vital for profitability. Learn effective techniques to boost sales and enhance your profits.
28,505 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
As hyperscalers pour money into AI and data centers, a select pair of stocks stands out for long-term holders. Vertiv...
Two oil-sector players, Occidental Petroleum and Energy Transfer, duke it out for the spot in a diversified portfolio...
SpaceX going public soon would shake investor interest in the space economy. This guide shows how to position yoursel...
SoundHound AI is pursuing an enterprise voice AI niche built on data ownership and brand protection. This article bre...
Robinhood once disrupted the trading scene with free commissions. As SpaceX eyes a public debut, investors wonder if ...
Macerich faces a retail landscape that’s evolved in 2025. This deep dive breaks down the factors shaping macerich (ma...
Navitas Semiconductor shares moved sharply higher as investors weighed strong earnings against exciting long-term gro...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...
A major asset manager boosted its stake in Boot Barn, signaling confidence in the westernwear retailer. This piece br...
Redistricting battles aren’t just about politics. They can ripple through local housing markets, shaping demand, lend...
As 2025 unfolds, sight sciences (sght) 2025 becomes a focal point for ophthalmology investors. This guide breaks down...